Pelosi Releases Plan To Control Pricing Of Prescription Drugs
House Speaker Nancy Pelosi, trying to seize the agenda on a top consumer issue, announced an ambitious prescription drug plan Thursday that would allow Medicare to negotiate prices for seniors and younger people.
The proposal would direct Medicare to bargain over as many as 250, but no fewer than 25, of the costliest drugs. Insulin is on the list. Drugmakers that refuse to negotiate could face steep penalties. Companies that raise prices beyond inflation would have to pay rebates to Medicare.
The plan would limit copays for seniors covered by Medicare’s “Part D” prescription drug program to $2,000. Medicare-negotiated prices would be available to other buyers, such as employer health plans.
It’s shaping up as a high-stake gamble for all sides in Washington. Polls show that high drug prices have Americans worried, and regardless of party affiliation, they want Congress to act. As a candidate, Donald Trump called for Medicare negotiations but then later seemed to drop the idea.
Pelosi (D-CA) said her goal is a deal that Trump can sign onto and that could pass the GOP-controlled Senate.
“We don’t want a political issue at the polls,” Pelosi said at a news conference. “We want a solution in Congress, and we want it now.”
The 2003 law that created Medicare’s prescription drug benefit barred the program from negotiating prices, a restriction Democrats have long opposed. Most Republicans say they believe price negotiations are best left to private players such as insurance companies.
The legislation leans left politically and appears to be tailor-made for Pelosi’s Democratic majority in the House. But in a signal that Pelosi wants a deal, it also incorporates ideas from the Trump administration and from Republican and Democratic senators.
Pelosi’s proposal would:
—authorize Medicare to negotiate prices for up to 250 drugs with the greatest total cost to society. That includes pharmacy drugs under the Part D prescription benefit, and Part B medications dispensed in doctors’ offices, such as many cancer drugs. Medicare would negotiate for as many drugs as possible on a list refreshed annually, but no fewer than 25. The maximum price would be determined using a blend of international prices, similar to a more limited proposal from the administration. Drug companies that balk at making a deal would face penalties that start at 65 percent of sales for the drug at issue, and escalate if they hold out.
—require drugmakers to pay rebates to Medicare if they raise prices beyond the increase in inflation. That idea resembles a plan from Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore. Their proposal has cleared a key committee, with Trump’s support. But many Senate Republicans oppose inflation rebates, and it’s unclear what Majority Leader Mitch McConnell, R-Ky., plans to do next.
—limit what seniors pay out of pocket for their medications to $2,000 a year. Currently, Medicare’s pharmacy benefit has no cap on copays, and the advent of drugs costing hundreds of thousands of dollars a year has left some seniors saddled with bills that rival a mortgage payment. An out-of-pocket limit is part of the Grassley-Wyden bill and is backed by the administration.
For now, criticism of the industry — from Trump and lawmakers of both parties — appears to be having an effect on prices.
The Commerce Department’s inflation index for prescription drug prices has declined in seven of the past eight months, which is highly unusual. That index includes lower-cost generic drugs.
For brand-name drugs, a recent Associated Press analysis shows that prices are still going up on average, but at a slower pace. Costly brand-name drugs that translate to steep copays are the top concern for consumers.
The AP analysis found that in the first seven months of 2019, drugmakers raised list prices for brand name medicines by a median, or midpoint, of 5 percent. That’s a slowdown. Prices were going up 9 percent or 10 percent over those months the prior four years.
Still, there were 37 price increases for every decrease in the first seven months of 2019.